Advertisement

Topics

Syros Pharmaceuticals Inc SYRS Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

19:01 EDT 10 Aug 2017 | BioPortfolio Reports

Summary

Syros Pharmaceuticals Inc Syros is a biopharmaceutical company that develops medicines for the treatment of cancer, immunemediated diseases, and other diseases. The company's pipeline products include SY1425, an oral, potent and selective RARa agonist that are used to treat patients with acute myeloid leukemia AML and myelodysplastic syndrome MDS. It also provides SY1365, potent and selective small molecule inhibitor of CDK7 that are used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors offers services such as gene regulation, new medicines development, genes control, proprietary drug development platform, integrated gene control assay technologies, and computational biology, chemistry, and deep biologic insights solutions. Its gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. The company seeks to work in partnership with others biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US.

Syros Pharmaceuticals Inc Key Recent Developments

Jun 19,2017: Syros Presents Discovery of Key Genes Controlling the Autoimmune Response in Lupus in LateBreaking Oral Presentation at FOCIS Meeting
Jun 12,2017: Syros Appoints Srinivas Akkaraju to Its Board of Directors
May 15,2017: Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
May 08,2017: Syros Announces LateBreaking Oral Presentation on its Research Identifying Key Genes that Control the Autoimmune Response in Lupus at FOCIS Meeting
Mar 20,2017: Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

This comprehensive SWOT profile of Syros Pharmaceuticals Inc provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Syros Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.

The profile contains critical company information including*, x000D
x000D
Business description A detailed description of the company's operations and business divisions.x000D
Corporate strategy Analyst's summarization of the company's business strategy.x000D
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D
Company history Progression of key events associated with the company.x000D
Major products and services A list of major products, services and brands of the company.x000D
Key competitors A list of key competitors to the company.x000D
Key employees A list of the key executives of the company.x000D
Executive biographies A brief summary of the executives' employment history.x000D
Key operational heads A list of personnel heading key departments/functions.x000D
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D
Key manufacturing facilities A list of key manufacturing facilities of the company.x000D
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D
x000D
Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,x000D
x000D
You get detailed information about the company and its operations to identify potential customers and suppliers.x000D
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D
x000D
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D
x000D
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D
x000D
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D
x000D
Gain key insights into the company for academic or business research.x000D
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Original Article: Syros Pharmaceuticals Inc SYRS Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

NEXT ARTICLE

More From BioPortfolio on "Syros Pharmaceuticals Inc SYRS Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...